
Core Viewpoint - Aclarion, Inc. will execute a 1-for-16 reverse stock split of its common stock effective January 4, 2024, to meet Nasdaq listing standards and increase its stock price above $1.00 [1][2][4] Group 1: Reverse Stock Split Details - The reverse stock split was approved by stockholders on March 24, 2023, and the Board of Directors set the ratio at 1-for-16 [2] - Post-split, the number of outstanding shares will decrease from approximately 13.4 million to about 840,000 [4] - The reverse stock split will not affect the authorized number of shares, and fractional shares will be rounded up to the nearest whole share [3][4] Group 2: Impact on Securities - The reverse stock split will also apply to outstanding warrants, stock options, and restricted stock units, with adjustments made to the number of shares and exercise prices [3] - A new CUSIP number (655187201) will be assigned to the shares, which will begin trading on a split-adjusted basis on January 4, 2024 [3] Group 3: Company Overview - Aclarion is a healthcare technology company focused on chronic low back pain, utilizing Magnetic Resonance Spectroscopy (MRS) and proprietary algorithms through its Nociscan platform [5] - Nociscan is designed to help physicians differentiate between painful and non-painful discs in the lumbar spine, providing critical insights for treatment optimization [5]